NO20091469L - Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer - Google Patents
Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorerInfo
- Publication number
- NO20091469L NO20091469L NO20091469A NO20091469A NO20091469L NO 20091469 L NO20091469 L NO 20091469L NO 20091469 A NO20091469 A NO 20091469A NO 20091469 A NO20091469 A NO 20091469A NO 20091469 L NO20091469 L NO 20091469L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- treatment
- compounds
- benzoxazoles
- oxazole
- Prior art date
Links
- 150000000183 1,3-benzoxazoles Chemical class 0.000 title 1
- RMMKGDVKSFHHAX-UHFFFAOYSA-N 1,3-oxazole;pyridine Chemical class C1=COC=N1.C1=CC=NC=C1 RMMKGDVKSFHHAX-UHFFFAOYSA-N 0.000 title 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 238000011282 treatment Methods 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- -1 2,7-disubstituted benzoxazole Chemical class 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 abstract 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 abstract 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06120733A EP1900729A1 (en) | 2006-09-15 | 2006-09-15 | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
| PCT/EP2007/007983 WO2008031594A1 (en) | 2006-09-15 | 2007-09-13 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20091469L true NO20091469L (no) | 2009-04-15 |
Family
ID=37717673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20091469A NO20091469L (no) | 2006-09-15 | 2009-04-15 | Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8629168B2 (enExample) |
| EP (2) | EP1900729A1 (enExample) |
| JP (1) | JP5325105B2 (enExample) |
| KR (1) | KR20090064389A (enExample) |
| CN (1) | CN101516860B (enExample) |
| AR (1) | AR062786A1 (enExample) |
| AT (1) | ATE532774T1 (enExample) |
| AU (1) | AU2007296916B2 (enExample) |
| BR (1) | BRPI0716841A2 (enExample) |
| CA (1) | CA2660987A1 (enExample) |
| CL (1) | CL2007002669A1 (enExample) |
| CO (1) | CO6150142A2 (enExample) |
| CR (1) | CR10639A (enExample) |
| EA (1) | EA200900388A1 (enExample) |
| ES (1) | ES2377148T3 (enExample) |
| GT (1) | GT200900056A (enExample) |
| IL (1) | IL196860A0 (enExample) |
| MA (1) | MA30723B1 (enExample) |
| MX (1) | MX2009002812A (enExample) |
| NO (1) | NO20091469L (enExample) |
| PA (1) | PA8748101A1 (enExample) |
| PE (1) | PE20080842A1 (enExample) |
| PL (1) | PL2066647T3 (enExample) |
| PT (1) | PT2066647E (enExample) |
| SM (1) | SMP200900023B (enExample) |
| TN (1) | TN2009000070A1 (enExample) |
| TW (1) | TW200819444A (enExample) |
| UY (1) | UY30587A1 (enExample) |
| WO (1) | WO2008031594A1 (enExample) |
| ZA (1) | ZA200900477B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| MX2011000211A (es) * | 2008-07-15 | 2011-03-03 | Sanofi Aventis | Oxazolopirimidinas como agonistas del receptor edg-1. |
| US20100041891A1 (en) * | 2008-08-12 | 2010-02-18 | Takeda Pharmaceutical Company Limited | Amide compound |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| WO2010061971A1 (ja) | 2008-11-28 | 2010-06-03 | 興和株式会社 | ピリジン－３－カルボキシアミド誘導体 |
| WO2011078360A1 (ja) | 2009-12-24 | 2011-06-30 | 武田薬品工業株式会社 | アミド化合物 |
| TWI485153B (zh) * | 2010-01-13 | 2015-05-21 | Sanofi Aventis | ２，５，７－經取代唑并嘧啶衍生物 |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| US8580816B2 (en) * | 2011-07-07 | 2013-11-12 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
| US8907093B2 (en) * | 2011-07-07 | 2014-12-09 | Sanofi | Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| CN103102359B (zh) * | 2011-11-15 | 2016-11-09 | 江苏先声药业有限公司 | 嘧啶类化合物及其应用 |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| WO2014075318A1 (zh) * | 2012-11-19 | 2014-05-22 | 江苏先声药业有限公司 | 嘧啶类化合物及其应用 |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| CN103664759A (zh) * | 2013-12-06 | 2014-03-26 | 常熟市联创化学有限公司 | 一种3-羟基-2-硝基吡啶的制备方法 |
| WO2015117147A1 (en) | 2014-02-03 | 2015-08-06 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| BR112016017993A2 (pt) | 2014-02-03 | 2017-08-08 | Quadriga Biosciences Inc | Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos |
| WO2016047678A1 (ja) * | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| KR20180035894A (ko) | 2015-08-03 | 2018-04-06 | 콰드리가 바이오사이언시스 인코포레이티드 | 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체 및 이들의 용도 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022251597A1 (en) | 2021-05-28 | 2022-12-01 | Verge Analytics, Inc. | Methods of treating neurological disorders with modulators of ribosomal protein s6 kinase alpha-1 (rsk1) and ribosomal protein s6 kinase alpha-3 (rsk2) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60037345T2 (de) * | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| DE10344223A1 (de) * | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| EP1674467A1 (en) * | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| CA2620127A1 (en) * | 2005-09-02 | 2007-03-08 | F. Hoffmann-La Roche Ag | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives |
| WO2008009458A1 (en) * | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
-
2006
- 2006-09-15 EP EP06120733A patent/EP1900729A1/en not_active Ceased
-
2007
- 2007-09-12 UY UY30587A patent/UY30587A1/es not_active Application Discontinuation
- 2007-09-13 EP EP07802300A patent/EP2066647B1/en active Active
- 2007-09-13 WO PCT/EP2007/007983 patent/WO2008031594A1/en not_active Ceased
- 2007-09-13 AR ARP070104060A patent/AR062786A1/es unknown
- 2007-09-13 AT AT07802300T patent/ATE532774T1/de active
- 2007-09-13 MX MX2009002812A patent/MX2009002812A/es active IP Right Grant
- 2007-09-13 JP JP2009527741A patent/JP5325105B2/ja not_active Expired - Fee Related
- 2007-09-13 PT PT07802300T patent/PT2066647E/pt unknown
- 2007-09-13 ES ES07802300T patent/ES2377148T3/es active Active
- 2007-09-13 AU AU2007296916A patent/AU2007296916B2/en not_active Ceased
- 2007-09-13 PL PL07802300T patent/PL2066647T3/pl unknown
- 2007-09-13 BR BRPI0716841-1A2A patent/BRPI0716841A2/pt not_active IP Right Cessation
- 2007-09-13 EA EA200900388A patent/EA200900388A1/ru unknown
- 2007-09-13 CA CA002660987A patent/CA2660987A1/en not_active Abandoned
- 2007-09-13 US US12/440,298 patent/US8629168B2/en not_active Expired - Fee Related
- 2007-09-13 KR KR1020097005248A patent/KR20090064389A/ko not_active Withdrawn
- 2007-09-13 PE PE2007001237A patent/PE20080842A1/es not_active Application Discontinuation
- 2007-09-13 CN CN2007800339907A patent/CN101516860B/zh not_active Expired - Fee Related
- 2007-09-14 CL CL200702669A patent/CL2007002669A1/es unknown
- 2007-09-14 PA PA20078748101A patent/PA8748101A1/es unknown
- 2007-09-14 TW TW096134606A patent/TW200819444A/zh unknown
-
2009
- 2009-01-21 ZA ZA200900477A patent/ZA200900477B/xx unknown
- 2009-02-02 IL IL196860A patent/IL196860A0/en unknown
- 2009-02-26 CR CR10639A patent/CR10639A/es not_active Application Discontinuation
- 2009-02-27 TN TN2009000070A patent/TN2009000070A1/fr unknown
- 2009-03-10 CO CO09024347A patent/CO6150142A2/es unknown
- 2009-03-11 GT GT200900056A patent/GT200900056A/es unknown
- 2009-03-30 MA MA31738A patent/MA30723B1/fr unknown
- 2009-04-09 SM SM200900023T patent/SMP200900023B/it unknown
- 2009-04-15 NO NO20091469A patent/NO20091469L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20091469L (no) | Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer | |
| NO20092529L (no) | Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| NO20072259L (no) | Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
| NO20092293L (no) | Sulfonyl-fenyl-2H-[1,2,4]oksodiazol-5-onderivater, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytiske midler | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| BRPI0809998B8 (pt) | composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas | |
| NO20071246L (no) | Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer. | |
| NO20076659L (no) | Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer | |
| NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| NO20082643L (no) | Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft | |
| NO20064201L (no) | Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling | |
| PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
| NO20085217L (no) | Effektive pyrimidinderivater i behandlingen av kreft | |
| MX2025010920A (es) | Compuestos quimicos | |
| TNSN06411A1 (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
| NO20055892L (no) | Karboksylsyrederivater | |
| NO20070295L (no) | Nye CIS-imidazoliner | |
| NO20071109L (no) | Indol-2-karboksamidinderivater som NMDA-reseptorantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |